Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357759 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
A Phase 1 study of Rheumatoid Arthritis, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT01357759 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Morphotek. The registered enrollment target is 20 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01357759, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
Conditions Studied
Interventions
- DRUG MORAb-022
Study Locations (5)
California
- Axis Clinical Trials - Los Angeles
Florida
- Seaview Jacksonville, LLC - Jacksonville
Oklahoma
- Lynn Health Science Institute - Oklahoma City
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Other
- Pharmaceutical Research Associates Group B.V. - Zuidlaren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357759
The ClinicalTrials.gov registry entry for NCT01357759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which MORAb-022 is the first listed.
NCT01357759 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT01357759 about?
NCT01357759 is a clinical study titled "Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects". This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
What is the current status of trial NCT01357759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-05. Estimated completion is 2014-07.
What conditions does trial NCT01357759 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01357759?
The interventions under investigation include: MORAb-022 (DRUG).
Who is sponsoring clinical trial NCT01357759?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357759 being conducted?
This trial has 5 study locations across California, Florida, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.